OBJECTIVE: The initial data of the International Study on Acute Coronary Syndromes - ST Elevation Myocardial Infarction COVID-19 showed in Europe a remarkable reduction in primary percutaneous coronary intervention procedures and higher in-hospital mortality during the initial phase of the pandemic as compared with the prepandemic period. The aim of the current study was to provide the final results of the registry, subsequently extended outside Europe with a larger inclusion period (up to June 2020) and longer follow-up (up to 30 days). METHODS: This is a retrospective multicentre registry in 109 high-volume primary percutaneous coronary intervention (PPCI) centres from Europe, Latin America, South-East Asia and North Africa, enrolling 16 674 patients with ST segment elevation myocardial infarction (STEMI) undergoing PPPCI in March/June 2019 and 2020. The main study outcomes were the incidence of PPCI, delayed treatment (ischaemia time >12 hours and door-to-balloon >30 min), in-hospital and 30-day mortality. RESULTS: In 2020, during the pandemic, there was a significant reduction in PPCI as compared with 2019 (incidence rate ratio 0.843, 95% CI 0.825 to 0.861, p<0.0001). This reduction was significantly associated with age, being higher in older adults (>75 years) (p=0.015), and was not related to the peak of cases or deaths due to COVID-19. The heterogeneity among centres was high (p<0.001). Furthermore, the pandemic was associated with a significant increase in door-to-balloon time (40 (25-70) min vs 40 (25-64) min, p=0.01) and total ischaemia time (225 (135-410) min vs 196 (120-355) min, p<0.001), which may have contributed to the higher in-hospital (6.5% vs 5.3%, p<0.001) and 30-day (8% vs 6.5%, p=0.001) mortality observed during the pandemic. CONCLUSION: Percutaneous revascularisation for STEMI was significantly affected by the COVID-19 pandemic, with a 16% reduction in PPCI procedures, especially among older patients (about 20%), and longer delays to treatment, which may have contributed to the increased in-hospital and 30-day mortality during the pandemic. TRIAL REGISTRATION NUMBER: NCT04412655.

• MeSH
• čas zasáhnout při rozvinutí nemoci trendy   MeSH
• časové faktory MeSH
• COVID-19 * MeSH
• hodnocení rizik MeSH
• incidence MeSH
• infarkt myokardu s elevacemi ST úseků diagnóza   mortalita   terapie   MeSH
• kardiologové trendy   MeSH
• koronární angioplastika škodlivé účinky   mortalita   trendy   MeSH
• lékařská praxe - způsoby provádění trendy   MeSH
• lidé středního věku MeSH
• lidé MeSH
• mortalita v nemocnicích trendy   MeSH
• registrace MeSH
• retrospektivní studie MeSH
• rizikové faktory MeSH
• senioři MeSH
• výsledek terapie MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• multicentrická studie MeSH

BACKGROUND: It has been suggested the COVID pandemic may have indirectly affected the treatment and outcome of STEMI patients, by avoidance or significant delays in contacting the emergency system. No data have been reported on the impact of diabetes on treatment and outcome of STEMI patients, that was therefore the aim of the current subanalysis conducted in patients included in the International Study on Acute Coronary Syndromes-ST Elevation Myocardial Infarction (ISACS-STEMI) COVID-19. METHODS: The ISACS-STEMI COVID-19 is a retrospective registry performed in European centers with an annual volume of > 120 primary percutaneous coronary intervention (PCI) and assessed STEMI patients, treated with primary PCI during the same periods of the years 2019 versus 2020 (March and April). Main outcomes are the incidences of primary PCI, delayed treatment, and in-hospital mortality. RESULTS: A total of 6609 patients underwent primary PCI in 77 centers, located in 18 countries. Diabetes was observed in a total of 1356 patients (20.5%), with similar proportion between 2019 and 2020. During the pandemic, there was a significant reduction in primary PCI as compared to 2019, similar in both patients with (Incidence rate ratio (IRR) 0.79 (95% CI: 0.73-0.85, p < 0.0001) and without diabetes (IRR 0.81 (95% CI: 0.78-0.85, p < 0.0001) (p int = 0.40). We observed a significant heterogeneity among centers in the population with and without diabetes (p < 0.001, respectively). The heterogeneity among centers was not related to the incidence of death due to COVID-19 in both groups of patients. Interaction was observed for Hypertension (p = 0.024) only in absence of diabetes. Furthermore, the pandemic was independently associated with a significant increase in door-to-balloon and total ischemia times only among patients without diabetes, which may have contributed to the higher mortality, during the pandemic, observed in this group of patients. CONCLUSIONS: The COVID-19 pandemic had a significant impact on the treatment of patients with STEMI, with a similar reduction in primary PCI procedures in both patients with and without diabetes. Hypertension had a significant impact on PCI reduction only among patients without diabetes. We observed a significant increase in ischemia time and door-to-balloon time mainly in absence of diabetes, that contributed to explain the increased mortality observed in this group of patients during the pandemic. TRIAL REGISTRATION NUMBER: NCT04412655.

• MeSH
• čas zasáhnout při rozvinutí nemoci trendy   MeSH
• časové faktory MeSH
• COVID-19 diagnóza   epidemiologie   mortalita   MeSH
• diabetes mellitus diagnóza   epidemiologie   mortalita   MeSH
• hypertenze epidemiologie   MeSH
• infarkt myokardu s elevacemi ST úseků mortalita   terapie   MeSH
• koronární angioplastika škodlivé účinky   mortalita   trendy   MeSH
• lidé středního věku MeSH
• lidé MeSH
• mortalita v nemocnicích trendy   MeSH
• registrace MeSH
• retrospektivní studie MeSH
• rizikové faktory MeSH
• senioři MeSH
• výsledek terapie MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• multicentrická studie MeSH
• práce podpořená grantem MeSH
• srovnávací studie MeSH
• Geografické názvy
• Evropa MeSH

BACKGROUND: Acute IH is a common surgical presentation. Despite new guidelines being published recently, a number of important questions remained unanswered including the role of taxis, as initial non-operative management. This is particularly relevant now due to the possibility of a lack of immediate surgical care as a result of COVID-19. The aim of this review is to assess the role of taxis in the management of emergency inguinal hernias. METHODS: A review of the literature was undertaken. Available literature published until March 2019 was obtained and reviewed. 32,021 papers were identified, only 9 were of sufficient value to be used. RESULTS: There was a large discrepancy in the terminology of incarcerated/strangulated used. Taxis can be safely attempted early after the onset of symptoms and is effective in about 70% of patients. The possibility of reduction en-mass should be kept in mind. Definitive surgery to repair the hernia can be delayed by weeks until such time as surgery can be safely arranged. CONCLUSIONS: The use of taxis in emergency inguinal hernia is a useful first line of treatment in areas or situations where surgical care is not immediately available, including the COVID-19 pandemic. Emergency surgery remains the mainstay of management in the strangulated hernia setting.

• MeSH
• Betacoronavirus MeSH
• čas zasáhnout při rozvinutí nemoci trendy   MeSH
• COVID-19 MeSH
• dostupnost zdravotnických služeb trendy   MeSH
• inguinální hernie terapie   MeSH
• klinické rozhodování MeSH
• kontrola infekce metody   MeSH
• konzervativní terapie metody   MeSH
• koronavirové infekce * epidemiologie   prevence a kontrola   MeSH
• lidé MeSH
• muskuloskeletální manipulace metody   MeSH
• operace kýly metody   MeSH
• pandemie * prevence a kontrola   MeSH
• SARS-CoV-2 MeSH
• urgentní zdravotnické služby * metody   trendy   MeSH
• virová pneumonie * epidemiologie   prevence a kontrola   MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• přehledy MeSH

Cíl: Cílem této práce bylo zhodnotit sociodemografi cké, osobní, situační a časové faktory, které ovlivňují délku rozhodování pacientů s akutním koronárním syndromem (AKS) při vyhledávání první pomoci. Metodika: Do naší studie jsme zařadili 83 konsekutivních pacientů, kteří byli v období od prosince 2018 do března 2019 hospitalizováni na našem pracovišti pro infarkt myokardu s elevacemi úseku ST (STEMI). Pacienti odpovídali formou dotazníku na otázky týkající se informovanosti o AKS, důvodů přednemocničního zdržení. Výsledky: Celkově bylo zařazeno 83 pacientů, z toho 63 mužů a 20 žen, medián věku souboru dosahoval 63 let. Pouze 15 pacientů (18,1 %) již v minulosti podstoupilo intervenci na koronárních tepnách. Osmatřicet pacientů (45,8 %) znalo příznaky AKS a 36 pacientů (43,4 %) znalo minimálně dva rizikové faktory ischemické choroby srdeční (ICHS). Medián časového zdržení od vzniku symptomů do kontaktování lékařské pomoci byl 120 minut. Pětapadesát pacientů (66,3 %) vyhledalo lékařskou pomoc do tří hodin od vzniku potíží. Průměrný věk mužů byl 62,3 roku a medián přednemocničního zdržení činil u mužů 120 minut, zatímco u žen dosahoval průměrný věk 66,1 roku a medián přednemocničního zdržení 165 minut. Medián zdržení u vysokoškolsky vzdělaných pacientů (n = 4) byl 52,5 min, 120 minut u středoškolsky vzdělaných pacientů (n = 57) a 112,5 minuty u pacientů se základním vzděláním (n = 22). Medián zdržení u pacientů se znalostmi symptomů ICHS (n = 38) byl 120 minut a u pacientů bez znalosti symptomů (n = 45) rovněž 120 minut. Stejně tak se pacienti s primomanifestací ICHS (n = 68) nelišili v přednemocničním zdržení od pacientů, kteří již v minulosti absolvovali perkutánní koronární intervenci (n = 15). Medián byl shodně 120 minut. Mezi důvody zdržení patřily bolesti zad v 31,3 % (n = 26), bolesti žaludku v 7,2 % (n = 6), nespecifi cké bolesti v 6 % (n = 5), plicní potíže v 3,6 % (n = 3), 19,3 % pacientů (n = 16) nechtělo zatěžovat lékaře, 15,7 % pacientů (n = 13) nevědělo, že si situace žádá akutní řešení, 8,4 % pacientů (n = 7) nemělo čas a 8,4 % (n = 7) se bálo lékařského kontaktu. Závěr: V našem souboru byl medián časového zdržení od vzniku potíží do prvního lékařského kontaktu 120 minut. Nejčastější příčinou byla záměna symptomů AKS za bolesti zad. Delší zdržení vykazovali pacienti starší 65 let, ženy a pacienti s nižším než vysokoškolským vzděláním. V časovém zdržení nebyl žádný rozdíl mezi pacienty se znalostí symptomů AKS či rizikových faktorů ICHS oproti pacientům bez znalosti symptomů AKS či rizikových faktorů ICHS. Stejně tak nebyl rozdíl mezi pacienty s předchozí perkutánní koronární intervencí oproti pacientům s primomanifestací ICHS.

The median of the time delay between the occurrence of symptoms and the contact of medical aid was 120 minutes. 55 patients (66.3%) called for help in less than 3 hours since their troubles started. The average age of men included in our study was 62.3 years and the median of the delay was 120 minutes among them. Whereas the average age among the women was 66.1 years and the delay before their admission was 165 minutes. The median among the people with tertiary education (n = 4) was 52.5 minutes, it was 120 minutes among patients with secondary education (n = 57) and it was 112.5 minutes among patients with primary education only (n = 22). The median of the delay among the patients who were aware of the symptoms of CHD (n = 38) was 120 minutes while it was the same also among the patients who were not aware of the symptoms (n = 45). Similarly, there was no difference in the median of the delay between the patients with a primomanifestation of CHD (n = 68) and the patients with a previously performed percutaneous coronary intervention (n = 15) – it was 120 minutes in both groups. The patients mentioned as the causes of the delay back aches (31.3%; n = 26), stomach aches (7.2%; n = 6), pulmonary diffi culties (3.6%; n = 3); 19.3% of the patients (n = 16) did not want to bother the physician; 15.7% (n = 13) were not aware of the fact that the situation deserves an acute resolution; 8.4% of the patients (n = 7) did not have time to resolve the problems and 8.4% of the patients (n = 7) were afraid of a contact with a physician. Conclusion: In our group the median of the delay between the fi rst occurrence of the symptoms and the fi rst medical contact was 120 minutes. The confusion between ACS symptoms and a back ache was the most frequent cause of the delay. The patients who were older than 65 years of age, women and patients without higher education evince a longer delay. There was no difference in the delay between the patients who were aware of ACS symptoms (or CHD risk factors) and the patients who were not aware of ACS symptoms (or CHD risk factors). Similarly there was no difference between the patients with a primomanifestation of CHD and patients with a previously performed percutaneous coronary intervention.

• MeSH
• akutní koronární syndrom MeSH
• čas zasáhnout při rozvinutí nemoci statistika a číselné údaje   trendy   MeSH
• časové faktory MeSH
• infarkt myokardu s elevacemi ST úseků * diagnóza   epidemiologie   MeSH
• lidé MeSH
• urgentní zdravotnické služby metody   MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• hodnotící studie MeSH

BACKGROUND: Contemporary data regarding the impact of comorbidities on the clinical presentation and management of patients with severe aortic stenosis (AS) are scarce. METHODS: Prospective registry of severe patients with AS across 23 centres in nine European countries. RESULTS: Of the 2171 patients, chronic kidney disease (CKD 27.3%), left ventricular ejection fraction (LVEF) <50% (22.0%), atrial fibrillation (15.9%) and chronic obstructive pulmonary disease (11.4%) were the most prevalent comorbidities (49.3% none, 33.9% one and 16.8% ≥2 of these). The decision to perform aortic valve replacement (AVR) was taken in a comparable proportion (67%, 72% and 69%, in patients with 0, 1 and ≥2 comorbidities; p=0.186). However, the decision for TAVI was more common with more comorbidities (35.4%, 54.0% and 57.0% for no, 1 and ≥2; p<0.001), while the decision for surgical AVR (SAVR) was decreased with increasing comorbidity burden (31.9%, 17.4% and 12.3%; p<0.001). The proportion of patients with planned AVRs that were performed within 3 months was significantly higher in patients with 1 or ≥2 comorbidities than in those without (8.7%, 10.0% and 15.7%; p<0.001). Furthermore, the mean time to AVR was significantly shorter in patients with one (30.5 days) or ≥2 comorbidities (30.8 days) than in those without (35.7 days; p=0.012). Patients with reduced LVEF tended to be offered an AVR more frequently and with a shorter delay while patients with CKD were less frequently treated. CONCLUSIONS: Comorbidities in severe patients with AS affect the presentation and management of patients with severe AS. TAVI was offered more often than SAVR and performed within a shorter time period.

• MeSH
• aortální stenóza epidemiologie   patofyziologie   chirurgie   MeSH
• čas zasáhnout při rozvinutí nemoci trendy   MeSH
• časové faktory MeSH
• chirurgická náhrada chlopně trendy   MeSH
• chronická obstrukční plicní nemoc epidemiologie   MeSH
• chronická renální insuficience epidemiologie   MeSH
• fibrilace síní epidemiologie   MeSH
• funkce levé komory srdeční MeSH
• hodnocení rizik MeSH
• klinické rozhodování MeSH
• komorbidita MeSH
• lidé MeSH
• prevalence MeSH
• prospektivní studie MeSH
• registrace MeSH
• rizikové faktory MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• stupeň závažnosti nemoci MeSH
• tepový objem MeSH
• transkatetrální implantace aortální chlopně trendy   MeSH
• výsledek terapie MeSH
• Check Tag
• lidé MeSH
• mužské pohlaví MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• multicentrická studie MeSH
• práce podpořená grantem MeSH
• Geografické názvy
• Evropa MeSH

Background and Purpose- Mobile stroke units (MSUs) are known to increase the proportion of acute ischemic stroke (AIS) patients treated with intravenous thrombolysis (IVT) in the first golden hour (GH) after onset compared with hospital settings (HS). However, because of the low number of AIS patients treated with intravenous thrombolysis within this ultraearly time window in conventional care, characteristics, and outcome of this subgroup of AIS patients have not been compared between MSU and HS. Methods- MSU-GH patients were selected from the Berlin-based MSU (STEMO [Stroke Emergency Mobile]), whereas HS-GH patients were selected from the SITS-EAST (Safe Implementation of Treatments in Stroke-East) registry. The outcome events of interest included the rates of favorable functional outcome (modified Rankin Scale scores of 0 or 1), distribution of the modified Rankin Scale scores, and mortality after 3 months between MSU-GH and HS-GH groups. Results- We identified 117 MSU-GH (38.4% of 305 MSU-treated patients) and 136 HS-GH (0.9% of 15 591 HS-treated patients) eligible patients without prestroke disability. No significant differences were documented in the rates of favorable functional outcome (51.3% versus 46.2%, P=0.487) and mortality (7.7% versus 9.9%, P=0.576) at 3 months, or in the distribution of 3-month modified Rankin Scale scores between the 2 groups ( P=0.196). In multivariable logistic regression analyses, adjusting for potential confounders, MSU treatment was not associated with a significantly different likelihood of favorable functional outcome (odds ratio, 1.84 for MSU patients; 95% CI, 0.86-3.96) or mortality (odds ratio, 0.95; 95% CI, 0.28-3.20) at 3 months. Conclusions- There is no evidence that safety and efficacy of ultraearly intravenous thrombolysis for AIS differs when used in MSUs or in HS.

• MeSH
• čas zasáhnout při rozvinutí nemoci * trendy   MeSH
• cévní mozková příhoda diagnóza   farmakoterapie   MeSH
• hospitalizace * trendy   MeSH
• intravenózní podání MeSH
• ischemie mozku diagnóza   farmakoterapie   MeSH
• kohortové studie MeSH
• lidé středního věku MeSH
• lidé MeSH
• mobilní zdravotnické jednotky * MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• trombolytická terapie metody   MeSH
• výsledek terapie MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH